Michel Khrestchatisky

This inventor holds 7 USPTO granted patents and 1 published patent application, plus 3 CIPO patents and 4 EPO patents. Top assignees: Centre National De La Recherche Scientifique, Vect-Horus, Université´ D'aix-Marseille. Active years: 2014-2025.

USPTO Granted Patents = 7 (Patent Applications = 1)

% Patents Active = 85.7

CIPO Patents = 3 (Patent Applications = 5)

EPO Patents = 4 (Patent Applications = 12)

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 9(Granted Patents)

Company Filing History:

7 out of 5,383

Centre National De La Recherche Scientifique

Université´ D'aix-Marseille

patents

4. 1 out of 10

Université De La Méditerranée - Aix-Marseille Ii

patents

where one patent can have more than one assignee

Years Active: 2014-2025

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12465660 - COMPOSITIONS AND METHODS FOR CANCER IMAGING AND RADIOTHERAPY (2025-11-11),

2. 12152317 - Transferrin receptor-binding molecules, conjugates thereof and their uses (2024-11-26),

3. 11712486 - Compositions and methods for cancer imaging and radiotherapy (2023-08-01),

4. 9821072 - Activated neurotensin molecules and the uses thereof (2017-11-21),

5. 9328143 - Peptide derivatives and use thereof as carriers for molecules in the form of conjugates (2016-05-03),

6. 8877716 - Peptide derivatives, preparation and uses thereof (2014-11-04),

7. 8729029 - Peptide derivatives and use thereof as carriers for molecules in the form of conjugates (2014-05-20),

Title: Michel Khrestchatisky: Innovator in Cancer Research

Introduction

Michel Khrestchatisky is a prominent inventor based in Marseilles, France. He has made significant contributions to the field of cancer research through his innovative inventions. With a total of six patents to his name, Khrestchatisky has focused on developing novel therapeutic and diagnostic methods.

Latest Patents

Among his latest patents is the invention of transferrin receptor-binding molecules and their conjugates. This invention relates to Variable Domain of Camelid Heavy Chain-only (VHH) molecules that bind to the transferrin receptor (TfR). These molecules are designed to transport pharmaceutical or diagnostic agents into cells and organs, particularly in pathological conditions such as cancer. Another notable patent involves compositions and methods for cancer imaging and radiotherapy. This invention includes a conjugated compound that comprises a pharmaceutically acceptable marker and a peptide or pseudo-peptide capable of binding to the Low-Density Lipoprotein Receptor (LDLR). This compound is utilized in methods for labeling, detecting, and treating cancerous cells.

Career Highlights

Throughout his career, Khrestchatisky has worked with notable organizations, including Vect-Horus and the Centre National de la Recherche Scientifique. His work has significantly advanced the understanding and treatment of cancer, showcasing his dedication to improving patient outcomes.

Collaborations

Khrestchatisky has collaborated with esteemed colleagues such as Marion David and Yves Molino. These partnerships have further enriched his research and development efforts in the field of cancer therapeutics.

Conclusion

Michel Khrestchatisky stands out as an influential inventor in cancer research, with a focus on innovative solutions for diagnosis and treatment. His contributions continue to impact the medical field positively.